Renal Tumor Clinical Trial
Official title:
Renal Autotransplantation; Case Series
Verified date | March 2024 |
Source | Methodist Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Renal autotransplantation (RAT) is a method of removing a kidney from its place of origin in a patient, repairing it, and transplanting it in another location of the body, generally the iliac fossa of the same patient.RAT is a relatively new technique; the first ever RAT procedure in the US was performed in 1963. Advances in preservation and transplantation techniques have made RAT a modality that can be utilized in complex renal diseases. RAT is indicated for conditions such as renal vascular disease, nutcracker syndrome, pelvic venous congestion, pelvic trauma, refractory stone disease and, in some cases, loin pain hematuria syndrome and conventionally unresectable renal tumors. Irrespective of the excellent outcomes shown by RAT, the conventional open approach requires a large midline xiphoid-to-pubis or flank incision for donor nephrectomy with a second pelvic incision for renal transplantation into the iliac fossa.The current gold standard approach to RAT is a laparoscopic nephrectomy followed by open auto-transplantation. However, this approach still requires a large pelvic incision. Robotic technology enables us to perform more complex minimally invasive surgery. Gordon et al. performed and reported the first completely intracorporeal robotic RAT to repair a ureteral injury in 2014.
Status | Enrolling by invitation |
Enrollment | 30 |
Est. completion date | September 30, 2024 |
Est. primary completion date | September 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject was 18 years or older at the time of the procedure - Subject who has undergone robotic RAT irrespective of the underlying etiology. Exclusion Criteria: - Subjects who do not meet the inclusion criteria |
Country | Name | City | State |
---|---|---|---|
United States | Liver Institute of Methodist Dallas Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
Methodist Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Baseline patient characteristics | Demographics-age | January 2018 until June 2021 | |
Primary | Baseline patient characteristics- BMI | BMI, based on the American Society of Anesthesiologists status classification | January 2018 until June 2021 | |
Primary | Baseline patient characteristics- Tobacco use | Medical History: tobacco use | January 2018 until June 2021 | |
Primary | Baseline patient characteristics- Gender | Demographics: gender | January 2018 until June 2021 | |
Primary | Baseline patient characteristics- Hypertension | Medical History: hypertension | January 2018 until June 2021 | |
Primary | Baseline patient characteristics- Diabetes | Medical History: diabetes | January 2018 until June 2021 | |
Primary | Baseline patient characteristics-cardiopulmonary disease | Medical History: cardiopulmonary disease | January 2018 until June 2021 | |
Primary | Baseline patient characteristics-indication for RAT (Renal Autotransplantation | Medical History: indication for RAT (Renal Autotransplantation) | January 2018 until June 2021 | |
Primary | Baseline patient characteristics-lesions | Medical History: lesions | January 2018 until June 2021 | |
Primary | Baseline patient characteristics-previous renal revascularization | Medical History: previous renal revascularization | January 2018 until June 2021 | |
Primary | Baseline patient characteristics-serum creatinine level | Medical History: serum creatinine level | January 2018 until June 2021 | |
Primary | short-term clinical data-Adverse events, | Adverse events, re- admissions, re-operations related to the index procedure | up to 30 days post discharge | |
Primary | intraoperative characteristics-Operative time | Operative time | January 2018 until June 2021 | |
Primary | intraoperative characteristics-total OR time | total OR time | January 2018 until June 2021 | |
Primary | intraoperative characteristics-concomitant procedures | concomitant procedures | January 2018 until June 2021 | |
Primary | intraoperative characteristics-transfusions | transfusions | January 2018 until June 2021 | |
Primary | intraoperative characteristics-conversions | conversions | January 2018 until June 2021 | |
Primary | intraoperative characteristics-intraoperative adverse events | intraoperative adverse events | January 2018 until June 2021 | |
Primary | intraoperative characteristics-autotransplantation technique | autotransplantation technique | January 2018 until June 2021 | |
Primary | post-operative characteristics-Post-operative adverse events | Post-operative adverse events | January 2018 until June 2021 | |
Primary | post-operative characteristics-discharge status | discharge status | January 2018 until June 2021 | |
Primary | post-operative characteristics-hospital length of stay | hospital length of stay | January 2018 until June 2021 | |
Primary | post-operative characteristics-information on enhanced recovery program | information on enhanced recovery program | January 2018 until June 2021 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03900364 -
a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A | |
Completed |
NCT02862288 -
Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia.
|
Phase 1/Phase 2 | |
Completed |
NCT04096534 -
Normotonic Partial Nephrectomy as Novel Approach in Treating Small Renal Masses
|
N/A | |
Completed |
NCT04072224 -
Evaluation of the Reproducibility of Ablation Volumes at One Month After Microwave Treatment Compared to the Manufacturer's Abacus: on the Kidney, Liver and Lung
|
||
Recruiting |
NCT03747133 -
SABR for Renal Tumors
|
N/A | |
Recruiting |
NCT04506671 -
Percutaneous Cryoablation Versus Partial Nephrectomy for T1b Renal Tumor
|
N/A | |
Recruiting |
NCT05377632 -
Comparing Two Different Approaches in Robotic-Assisted Renal Surgery
|
N/A | |
Recruiting |
NCT03667885 -
Non-Invasive Diagnostics of Small Renal Masses
|
||
Completed |
NCT03841149 -
Volume 3D_US Kidney
|
||
Recruiting |
NCT05976607 -
Clinical Study of 18F -FAPI-RGD in Renal Tumor
|
||
Recruiting |
NCT06322745 -
Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy
|
N/A | |
Terminated |
NCT02581384 -
Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02335827 -
Irreversible Electroporation(IRE) For Unresectable Renal Tumors
|
N/A | |
Completed |
NCT05089006 -
Cost-effectivness of Robot-assisted Surgery Compared to Open Surgery for Partial Nephrectomy in Context of Renal Tumor
|
||
Recruiting |
NCT03810651 -
Pencil Beam Scanning in Patients With Renal Tumors
|
Early Phase 1 | |
Not yet recruiting |
NCT05572216 -
A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)
|
N/A | |
Recruiting |
NCT06076538 -
PET/MR for Characterization of Renal Masses (RMs)
|
||
Completed |
NCT01833728 -
A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy
|
N/A | |
Recruiting |
NCT04537247 -
A Comparative Study Between Open and Robotic Partial Nephrectomy in Treatment of High Complex Renal Tumors.
|
N/A |